Targeting the Androgen Receptor Pathway in Prostate Cancer: A PROTrACted Struggle.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 41160408.
- Also identified by DOI 10.1158/1078-0432.CCR-25-3045 and PMC identifier 12927871.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The androgen receptor (AR) is the most important therapeutic target for metastatic prostate cancer. Though clinical responses to AR inhibition are nearly universal, so is progression, usually accompanied by reactivation of AR signaling. A new small-molecule dual AR degrader/inhibitor shows promise in overcoming resistance and improving clinical outcomes. See related article by Nayak et al., p. 224.
Medical subject headings
- Receptors, Androgen
- Signal Transduction
- Prostatic Neoplasms
- Androgen Receptor Antagonists